NASDAQ : CTOR
Citius Oncology, Inc. — Financial statements
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 0.5295 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 56.00M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year October - September; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Selling, General & Admin | 45.38M | 17.10M | 15.65M | 7.88M | 2.86M |
| Research & Development | 3.39M | 6.42M | 4.93M | 4.24M | 6.86M |
| Operating Expenses | 52.79M | 23.52M | 20.57M | 12.12M | 9.71M |
| Operating Income | -47.47M | -23.52M | -20.57M | -12.12M | -9.71M |
| Interest Expense | -367.88K | -218.03K | |||
| Interest & Investment Income | 205.23K | 36.37K | |||
| Pretax Income | -45.87M | -23.70M | -20.57M | -12.12M | -9.71M |
| Income Tax Expense | 189.92K | 1.06M | 576.00K | 576.00K | 1.15M |
| Net Income | -46.06M | -24.76M | -21.15M | -12.70M | -10.87M |
| Net Income to Common | -46.06M | -24.76M | -21.15M | -12.70M | -10.87M |
| Shares Outstanding (Basic) | 93.41M | 73.27M | 68.05M | 67.50M | 33.75M |
| Shares Outstanding (Diluted) | 93.41M | 73.27M | 68.05M | 67.50M | 33.75M |
| EPS (Basic) | -0.49 | -0.34 | -0.31 | -0.19 | -0.32 |
| EPS (Diluted) | -0.49 | -0.34 | -0.31 | -0.19 | -0.32 |
| EBIT | -47.47M | -23.52M | -20.57M | -12.12M | -9.71M |
Balance sheet
Fiscal year October - September; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 16.56M | 3.92M | 112.00 | ||
| Cash & Short-Term Investments | 16.56M | 3.92M | 112.00 | ||
| Inventory | 22.63M | 22.29M | 8.27M | ||
| Prepaid Expenses | 2.83M | 1.33M | 2.70M | 7.73M | 2.69M |
| Total Current Assets | 42.71M | 27.54M | 10.97M | 7.73M | 2.69M |
| Long-Term Deferred Charges | 69.39M | 73.40M | 73.40M | 40.00M | 40.00M |
| Total Assets | 112.09M | 100.94M | 84.37M | 47.73M | 42.69M |
| Accounts Payable | 7.32M | 13.23M | 3.71M | 1.29M | 92.31K |
| Accrued Expenses | 35.82M | 13.61M | 588.81K | 19.76M | 5.75M |
| Other Current Liabilities | 15.65M | 22.65M | 28.40M | ||
| Total Current Liabilities | 58.79M | 49.49M | 32.70M | 21.05M | 5.85M |
| Long-Term Debt | 10.21M | 3.80M | 3.80M | ||
| Long-Term Deferred Tax Liabilities | 2.71M | 2.78M | 1.73M | 1.15M | 576.00K |
| Other Long-Term Liabilities | -1.00 | ||||
| Total Liabilities | 71.71M | 56.08M | 38.23M | 22.20M | 6.42M |
| Common Stock | 10.58K | 8.35K | 7.16K | 6.75K | 6.75K |
| Additional Paid-In Capital | 145.48M | 108.90M | 85.41M | 43.66M | 41.69M |
| Retained Earnings | -105.11M | -64.04M | -39.28M | -18.13M | -5.43M |
| Shareholders' Equity | 40.38M | 44.87M | 46.14M | 25.54M | 36.27M |
| Total Liabilities & Equity | 112.09M | 100.94M | 84.37M | 47.73M | 42.69M |
| Total Debt | 10.21M | 3.80M | 3.80M | ||
| Net Cash (Debt) | 6.35M | 124.80K | -3.80M | ||
| Net Cash Per Share | 0.07 | 0.00 | -0.06 | ||
| Filing Date Shares Outstanding | 105.76M | 84.80M | 71.55M | 67.50M | 67.50M |
| Total Common Shares Outstanding | 105.76M | 83.51M | 71.55M | 67.50M | 67.50M |
| Working Capital | -16.08M | -21.95M | -21.73M | -13.31M | -3.16M |
| Book Value Per Share | 0.38 | 0.54 | 0.64 | 0.38 | 0.54 |
| Tangible Book Value | 40.38M | 44.87M | 46.14M | 25.54M | 36.27M |
| Tangible Book Value Per Share | 0.38 | 0.54 | 0.64 | 0.38 | 0.54 |
Cash flow statement
Fiscal year October - September; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Net Income | -46.06M | -24.76M | -21.15M | -12.70M | -10.87M |
| Stock-Based Compensation | 13.34M | 8.32M | 7.50M | 1.97M | |
| Other Operating Activities | 189.92K | 1.06M | 576.00K | 576.00K | 1.15M |
| Change in Inventory | -4.05M | -12.65M | -2.13M | ||
| Change in Accounts Payable | -1.35M | 9.52M | 2.42M | 1.20M | 184.62K |
| Change in Other Net Operating Assets | 15.04M | 13.02M | 12.91M | 8.96M | 9.53M |
| Operating Cash Flow | -19.39M | -5.49M | 126.35K | ||
| Sale (Purchase) of Intangibles | -12.75M | -5.75M | -5.00M | ||
| Investing Cash Flow | -12.75M | -5.75M | -5.00M | ||
| Long-Term Debt Issued | 3.80M | ||||
| Net Debt Issued (Repaid) | 9.63M | 3.80M | |||
| Issuance of Common Stock | 39.96M | 15.17M | |||
| Other Financing Activities | -892.55K | 1.07M | |||
| Financing Cash Flow | 48.70M | 15.17M | 4.87M | ||
| Net Cash Flow | 16.56M | 3.92M | 112.00 | ||
| Levered Free Cash Flow | -31.17M | -8.13M | -1.94M | 4.55M | |
| Unlevered Free Cash Flow | -30.94M | -7.99M | -1.94M | 4.55M | |
| Cash Interest Paid | 400.18K | 187.39K | |||
| Change in Working Capital | 8.95M | 9.89M | 13.20M | 10.16M | 9.71M |
Ratios
Fiscal year October - September; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Market Capitalization | 64.52M | 169.53M | 99.11M | 96.29M | |
| Enterprise Value | 58.17M | 173.33M | |||
| Last Close Price | 0.55 | 2.03 | 1.39 | 10.77 | |
| Forward PE | 89.00 | ||||
| PB Ratio | 1.45 | 3.78 | 2.15 | 3.77 | |
| P/TBV Ratio | 1.66 | 3.78 | 2.15 | 3.77 | |
| P/OCF Ratio | 784.41 | ||||
| Debt / Equity Ratio | 0.25 | 0.09 | 0.08 | ||
| Net Debt / Equity Ratio | -0.16 | -0.00 | 0.08 | ||
| Quick Ratio | 0.29 | 0.08 | 0.00 | ||
| Current Ratio | 0.73 | 0.56 | 0.34 | 0.37 | 0.46 |
| Return on Equity (ROE) | -126.58% | -54.42% | -59.01% | -41.09% | |
| Return on Assets (ROA) | -29.12% | -15.87% | -19.47% | -16.76% | |
| Return on Capital Employed (ROCE) | -89.10% | -45.70% | -39.80% | -45.40% | -26.40% |
| Earnings Yield | -80.83% | -14.61% | -21.34% | -13.19% | |
| Buyback Yield / Dilution | -31.40% | -7.66% | -0.82% | -100.00% |